HeartBeam Earnings Call Transcripts
Fiscal Year 2026
-
Achieved key milestones in commercialization, clinical validation, and product development, including flagship accounts in four major geographies and a strategic AI partnership. Q1 2026 saw a 19% year-over-year reduction in cash burn, with a strengthened balance sheet and funding runway into 2027.
-
A novel at-home 12-lead ECG platform is launching with a subscription model targeting concierge cardiology, leveraging strong physician and patient demand. The company is expanding into ambulatory monitoring and AI-driven cardiac care, supported by clinical studies and strategic partnerships.
Fiscal Year 2025
-
FDA clearance for 12-lead ECG software enabled commercial launch and partnerships, with strong demand in concierge cardiology. Net loss narrowed, cash use declined, and 2026 will focus on scaling adoption, clinical studies, and AI development.
-
Q3 2025 saw continued progress toward FDA clearance for a novel at-home ECG system, with a net loss of $5.3M and cash use declining. Commercial launch is planned for early 2026, focusing on two U.S. regions and leveraging a new partnership for nationwide cardiologist coverage.
-
Q2 2025 saw reduced cash burn and strong progress toward FDA clearance for the 12-lead ECG software, with commercial launch preparations advancing in key markets. Strategic partnerships, industry recognition, and a robust capital strategy position the business for growth.
-
A novel cable-free ECG device is set to launch in the concierge medicine market by late 2025, targeting high-margin recurring revenue and leveraging strong clinical validation and FDA clearances. Expansion plans include AI-driven insights, heart attack detection, and integration into the extended wear patch market.
-
Key milestones achieved include FDA clearance for the foundational system, positive pivotal study results, and a strategic partnership with AccurKardia. Financial discipline remains strong, with $11.5 million raised and commercial launch targeted for late 2025 pending FDA approval.
Fiscal Year 2024
-
Achieved foundational FDA clearance and raised $11.5M to support commercialization of a novel cable-free ECG system. Early access program and pilot commercialization target a multi-billion dollar direct patient pay market, with FDA review of 12-lead software expected by year-end.
-
Q3 2024 saw a net loss of $4.98M and a $5.8M cash balance, with spending focused on R&D and clinical milestones. FDA clearance is expected soon, enabling an early access program and a 2025 commercial launch, though no significant revenue is anticipated next year.
-
AIMIGo, a cable-free 12-lead ECG device, is progressing through FDA review with a limited launch expected by year-end 2024. Q2 net loss widened to $5 million on higher R&D and G&A expenses, with $9.2 million in cash remaining. Clinical and AI milestones continue to advance.